3rd generation glp-1 Retatrutide is a “GLP-3” therapy, meaning it acts on three hormone receptors — GLP-1, GIP, and glucagon — to influence appetite regulation, blood sugar control, and energy expenditure. By working across these Transforming obesity: The advancement of

What Happens: GLP-1 medications cross the blood-brain barrier Activate receptors in appetite control regions Reduce hunger signals Increase satiety (feeling of fullness) Decrease reward response to food Reduce obsessive thoughts about food What You Experience: Less frequent hunger Feel satisfied with smaller portions Dont think about food constantly Reduced cravings for specific foods Easier to say no to unnecessary eating This is the primary mechanismyou naturally eat less because you genuinely want less food

Plant Cell Environ 43:20332053

The difference is the delivery device, since some products use an autoinjector pen while compounded semaglutide uses a vial and syringe

States Where BCBS Has Dropped GLP-1 Coverage The trend to watch in 2026 is BCBS affiliates pulling back on GLP-1 weight loss drug coverage

Drug reaction with eosinophilia and systemic symptoms (DRESS) in children

Same number of units drawn